<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03593499</url>
  </required_header>
  <id_info>
    <org_study_id>408-C-1401EA</org_study_id>
    <nct_id>NCT03593499</nct_id>
  </id_info>
  <brief_title>Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      This is an expanded access program for eligible participants and is designed to provide
      access to omaveloxolone for the treatment of unresectable or metastatic melanoma to patients
      who previously participated in the 408-C-1401 (REVEAL) study. To be considered for expanded
      access, a Principal Investigator from the REVEAL trial should submit a request to Reata
      Pharmaceuticals on behalf of the individual patient.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omaveloxolone</intervention_name>
    <other_name>RTA 408</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Jason Hurt, MD</last_name>
    <phone>469-442-4733</phone>
    <email>jason.hurt@reatapharma.com</email>
  </overall_contact>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>December 18, 2019</last_update_submitted>
  <last_update_submitted_qc>December 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>omaveloxolone</keyword>
  <keyword>expanded access</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

